Gastric epithelial cell modality and proton pump inhibitor

Tatsuhiro Masaoka, Hidekazu Suzuki, Toshifumi Hibi

Research output: Contribution to journalReview articlepeer-review

16 Citations (Scopus)


Proton pump inhibitors (PPls) are now commonly used for the treatment of acid related diseases such as peptic ulcer and reflux esophagitis. Because of their ability to produce direct inhibition of the proton pump, PPIs provide more sustained increase of the gastric pH than H2-receptor (H 2R) antagonists. Diverse reports have been published on gastric epithelial cell modality associated with PPI treatment both in animal models and clinical settings. The present review summarizes the recent accumulated evidence on gastric epithelial cell modality associated with PPI treatment, including the formation of gastric carcinoid tumors and fundic gland polyps, and the development of gastric mucosal atrophy. Long-term PPI treatment has been reported to cause enlargement of the parietal cells and enterochromaffin-like cells, and to decrease the number of chief cells without affecting A-like cell. Although the development of gastric carcinoid tumors after chronic PPI treatment has been reported in animal studies, no such occurrences have been demonstrated in humans. The effect of PPIs on the formation of fundic gland polyps and the development of atrophic gastritis should be investigated in future studies.

Original languageEnglish
Pages (from-to)191-196
Number of pages6
JournalJournal of Clinical Biochemistry and Nutrition
Issue number3
Publication statusPublished - 2008 May
Externally publishedYes


  • Chief cell
  • Gastric fundic gland
  • Ghrelin
  • Pariental cell
  • Proton pump inhibitor

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Clinical Biochemistry


Dive into the research topics of 'Gastric epithelial cell modality and proton pump inhibitor'. Together they form a unique fingerprint.

Cite this